Laboratory Corp of America (LH)

The American Hospital Association projects that some 98 million Americans will ultimately become infected with covid-19, resulting in 48 million hospitalizations. Of these, 480,000 may die. If these grim numbers prevail, covid-19 would be 10x to 15x worse than the deadliest flu season.

Every nation must come to grips with the reality of covid-19 infecting a large portion of their population, and the first step in battling the virus is to test to find out just who has it.

Testing is a big opportunity for investors

Laboratory Corp of America (LH) bills itself as the world’s leading health care diagnostics company. The North Carolina company had $11.6 billion in sales during 2019. They operate over 2,000 healthcare centres around the country. However, the best is yet to come.

Testing for covid-19 in the United States is about to ramp up substantially. LabCorp will play a central role. Managers have built a strong relationship with the Trump White House. Now the company is rolling out aggressive new testing targets.

A press release March 14 indicates LabCorp facilities will be capable of 10,000 tests per day by the end of next week, and 20,000 tests per day by the end of the month. This represents a massive new, unanticipated sales bonanza. It could last several quarters.

Its share price has been ravaged by the markets recently and now represents amazing value at $107. It was trading at almost $200 in February. Given the prospect of an uninterrupted new revenue stream, this seems extremely inexpensive. Buy now while you can still get it at these prices

Disclaimer: Capital 19 Pty Ltd ABN 17 124 264 366 AFSL 441891 (‘Capital 19’) believes the information contained is reliable, however, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. This communication is for general information only and was prepared for multiple distributions and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. Persons relying on this information should do so considering their specific investment objectives and financial situations. Any person considering action based on this communication must seek individual advice relevant to their circumstances and investment objectives. Subject to any liability which cannot be excluded under the relevant laws. Any opinions or forecasts reflect the judgment and assumptions of Capital 19 and its representatives based on information at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future. The investment manager certifies that all the views expressed in this document accurately reflect their views about the companies and securities referred to in this document and that their remuneration is not directly or indirectly related to the views. Capital 19, its directors, representatives, employees or related parties may have an interest in any of the companies and securities in this document and may earn revenue from the sale or purchase of any financial product referred to in this document or any advice. Past performance is not a reliable indicator of future performance. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this document is prohibited without obtaining prior written permission from Capital 19.